The Download: the mysteries surrounding weight-loss drugs, and the economic effects of AI
This newsletter covers recent developments in weight-loss drugs and the economic impacts of AI. It highlights the uncertainties surrounding GLP-1 drugs, despite their commercial success, and previews a discussion on the complex economic effects of AI.
-
Weight-loss drugs: While companies like Eli Lilly are thriving, questions remain about the long-term effects, potential risks during pregnancy, and use for postpartum weight loss. The drugs also don't appear to help with Alzheimer's.
-
AI's economic impact: The newsletter promotes a subscriber-only discussion about the nuanced and often debated effects of AI on various markets, part of a broader partnership between the Financial Times and MIT Technology Review.
-
Tech regulation pushback: Tech billionaires are reportedly amassing funds to fight against AI regulation in the US.
-
China's tech focus: China faces a potential humanoid robot "bubble" and is using permissive regulation to become an unstoppable innovation drive.
-
Scam Compounds: Even with the destruction of scam compounds in Myanmar, the issue continues as the operations merely relocate.
-
The success of Eli Lilly doesn't negate the need for more research into the safety and efficacy of weight-loss drugs.
-
The newsletter emphasizes the complexity of AI's impact, moving beyond simple optimism or pessimism, making it a nuanced conversation.
-
The "Must-Reads" section offers a diverse look into current tech, from submarine drones to the mysterious clock project by Jeff Bezos.